{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:10:25Z","timestamp":1768165825837,"version":"3.49.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:00:00Z","timestamp":1606003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:00:00Z","timestamp":1606003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s11239-020-02343-w","type":"journal-article","created":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T11:02:47Z","timestamp":1606042967000},"page":"597-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm"],"prefix":"10.1007","volume":"52","author":[{"given":"Jones T.","family":"Nauseef","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana I.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9239-5131","authenticated-orcid":false,"given":"Maria T.","family":"DeSancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,22]]},"reference":[{"key":"2343_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295\u2013306","journal-title":"J Thromb Haemost"},{"key":"2343_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","volume":"92","author":"R Cervera","year":"2018","unstructured":"Cervera R et al (2018) The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review. J Autoimmun 92:1\u201311","journal-title":"J Autoimmun"},{"key":"2343_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1182\/blood.2019003863","volume":"135","author":"S Chaturvedi","year":"2020","unstructured":"Chaturvedi S, Braunstein EM, Yuan X et al (2020) Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 135:239\u2013251","journal-title":"Blood"},{"key":"2343_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/BOR.0000000000000595","volume":"31","author":"AP Vreede","year":"2019","unstructured":"Vreede AP et al (2019) Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome. Curr Opin Rheumatol 31:231\u2013240","journal-title":"Curr Opin Rheumatol"},{"key":"2343_CR5","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMra1705454","volume":"378","author":"D Garcia","year":"2018","unstructured":"Garcia D, Erkan D (2018) Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 378:2010\u20132021","journal-title":"N Engl J Med"},{"key":"2343_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/MBC.0000000000000030","volume":"25","author":"LM Baumann Kreuziger","year":"2014","unstructured":"Baumann Kreuziger LM, Datta YH, Johnson AD, Zantek ND, Shanley R, Reding MT (2014) Monitoring anticoagulation in patients with an unreliable prothrombin time\/international normalized ratio: factor II versus chromogenic factor X testing. Blood Coagul Fibrinolysis 25:232\u2013236","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2343_CR7","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s40264-015-0337-1","volume":"38","author":"T-TL Nguyen","year":"2015","unstructured":"Nguyen T-TL, Palmaro A, Montastruc F et al (2015) Signal for thrombosis with eltrombopag and romiplostim: a disproportionality analysis of spontaneous reports within VigiBase\u00ae. Drug Saf 38:1179\u20131186","journal-title":"Drug Saf"},{"key":"2343_CR8","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1111\/jth.13763","volume":"15","author":"R Hisada","year":"2017","unstructured":"Hisada R, Kato M, Sugawara E et al (2017) Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study. J Thromb Haemost 15:1782\u20131787","journal-title":"J Thromb Haemost"},{"key":"2343_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4274\/tjh.2015.0197","volume":"33","author":"D Erkan","year":"2016","unstructured":"Erkan D, Salmon JE (2016) The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome. Turk J Haematol 33:1\u20137","journal-title":"Turk J Haematol"},{"key":"2343_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/ajt.12540","volume":"14","author":"BE Lonze","year":"2014","unstructured":"Lonze BE, Zachary AA, Magro CM et al (2014) Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 14:459\u2013465","journal-title":"Am J Transplant"},{"key":"2343_CR11","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.autrev.2016.09.010","volume":"15","author":"I Rodriguez-Pinto","year":"2016","unstructured":"Rodriguez-Pinto I, Moitinho M, Santacreu I et al (2016) Catastrophic antiphospholipid syndrome (CAPS): destructive analysis of 500 patients from the international CAPS registry. Autoimmun Rev 15:1120\u20131124","journal-title":"Autoimmun Rev"},{"key":"2343_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","volume":"130","author":"SA Merril","year":"2017","unstructured":"Merril SA, Brittingham ZD, Yuan X et al (2017) Eculizumab cessation in atypical hemolytic uremic syndrome. Blood 130:368\u2013372","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-020-02343-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-020-02343-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-020-02343-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T05:05:16Z","timestamp":1635224716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-020-02343-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,22]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["2343"],"URL":"https:\/\/doi.org\/10.1007\/s11239-020-02343-w","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,22]]},"assertion":[{"value":"10 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Maria T. DeSancho has participated in Advisory Boards for Apellis Pharmaceuticals, Bio-Products Laboratory and Sanofi-Genzyme. The other authors have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}